Beautiful Virgin Islands

Monday, Jul 21, 2025

COVID-19: Delaying second dose of Pfizer jab may leave elderly at risk of catching South African variant, study suggests

COVID-19: Delaying second dose of Pfizer jab may leave elderly at risk of catching South African variant, study suggests

Lab tests showed that one dose of the vaccine may not stimulate the immune system to produce enough antibodies to kill the virus.

Delaying the second dose of the Pfizer jab – the current government strategy - may leave some elderly patients at risk of infection by the South African variant, new research suggests.

Lab tests by scientists at Cambridge University showed that one dose of the vaccine may not stimulate the immune system to produce enough antibodies to kill the virus.

Only after a second dose would antibody levels be protective, according to preliminary data in the study, which has not yet been peer-reviewed.

Meanwhile, the South African variant has a mutation called E484K that helps it evade the immune system.

SOUTH AFRICAN VARIANT CASES



Some samples of the Kent variant have now been detected with the same mutation.

The Cambridge researchers tested blood samples from 26 people, 15 of them over 80, who had received one dose of the Pfizer jab against synthetic versions of both variants.

Antibodies in all volunteers were sufficient to kill the Kent variant.

But when the E484K mutation was added 10 times more antibodies were needed to neutralise the virus.

According to researchers, seven people had antibody levels that were insufficient to kill the virus after one dose of the vaccine, all of them over 80.

Only after a second dose, given three weeks later, were their antibody levels boosted to a level that killed the virus.

The study comes on the day Sky News analysis showed the number of deaths in the second wave of COVID-19 infections has now overtaken the number from the first.

Dr Dami Collier, one of the co-investigators, said: "Our data suggest that a significant proportion of people aged over 80 may not have developed protective neutralising antibodies against infection three weeks after their first dose of the vaccine.

"But it's reassuring to see that after two doses, serum from every individual was able to neutralise the virus."

Professor Ravi Gupta, the lead researcher, said: "Our work suggests the vaccine is likely to be less effective when dealing with this (E484K) mutation.

"B1.1.7 [the Kent variant] will continue to acquire mutations seen in the other variants of concern, so we need to plan for the next generation of vaccines to have modifications to account for new variants.

"We also need to scale up vaccines as fast and as broadly as possible to get transmission down globally."

A Department for Health and Social Care (DHSC) spokesperson said the decision to change vaccine dosage intervals (to spread them further apart) had come after a "thorough review of data" which showed the Pfizer/BioNTech vaccine was 89% effective in protection against COVID between 15 to 21 days after the first dose.

A DHSC statement said today's study had "assessed just one aspect of immunity, on a small cohort" and that getting vaccines deployed as quickly as possible to those at risk remained "our number one priority".

It concluded: "The Government is closely following the guidance of the Joint Committee on Vaccination and Immunisation and the UK's four Chief Medical Officers, which recommends we prioritise first doses of vaccine for as many people as possible"

The E484K variant helps the coronavirus evade the immune system and was found in 11 samples of some 200,000 that have been sequenced.

Sky's science correspondent Thomas Moore said the discovery of the E484K mutation was a "worrying development," as it could reduce the effectiveness of COVID vaccines and could also mean those who had been previously infected could be re-infected.

He said the evolution of E484K meant the virus had effectively "developed a superpower" which enabled it to not only infect cells, but also to beat the immune system.

"It changes shape so antibodies don't recognise it in the same way, and the fact that this mutation has been now picked up in some samples of the Kent variant is a twist - a worrying development," said Thomas Moore.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Defends Attorney General Pam Bondi Amid Epstein Memo Backlash
Renault Shares Drop as CEO Luca de Meo Announces Departure Amid Reports of Move to Kering
Senior Aides for King Charles and Prince Harry Hold Secret Peace Summit
Anti‑Semitism ‘Normalised’ in Middle‑Class Britain, Says Commission Co‑Chair
King Charles Meets David Beckham at Chelsea Flower Show
If the Department is Really About Justice: Ghislaine Maxwell Should Be Freed Now
NYC Candidate Zohran Mamdani’s ‘Antifada’ Remarks Spark National Debate on Political Language and Economic Policy
×